These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3465664)

  • 1. Factors affecting serum levels of CA 19-9 with special reference to benign hepatobiliary and pancreatic diseases.
    Sawabu N; Takemori Y; Toya D; Yoneshima M; Kidani H; Satomura Y; Ohta H; Hattori N
    Gastroenterol Jpn; 1986 Oct; 21(5):491-8. PubMed ID: 3465664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of serum CA125 values in patients with cancers of the digestive system.
    Haga Y; Sakamoto K; Egami H; Yoshimura R; Mori K; Akagi M
    Am J Med Sci; 1986 Jul; 292(1):30-4. PubMed ID: 3459357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Scheinin TM; Mäkelä O; Jalanko H
    Br J Cancer; 1986 Feb; 53(2):197-202. PubMed ID: 3456787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 19-9 and CA 50 in benign and malignant pancreatic and biliary diseases.
    Paganuzzi M; Onetto M; Marroni P; Barone D; Conio M; Aste H; Pugliese V
    Cancer; 1988 May; 61(10):2100-8. PubMed ID: 2834038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of human pancreatic cancer-associated antigen (SPan-1 antigen) in hepatobiliary and pancreatic diseases].
    Nakata B; Chung YS; Yokomatsu H; Tanaka H; Sawada T; Nishiwaki H; Satake K; Umeyama K; Seki S
    Nihon Shokakibyo Gakkai Zasshi; 1990 Apr; 87(4):1050-5. PubMed ID: 2376901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
    Haglund C
    Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
    Kuusela P; Haglund C; Roberts PJ
    Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases.
    Jalanko H; Kuusela P; Roberts P; Sipponen P; Haglund CA; Mäkelä O
    J Clin Pathol; 1984 Feb; 37(2):218-22. PubMed ID: 6198342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum DU-PAN-2 in the differential diagnosis of pancreatic cancer: influence of jaundice and liver dysfunction.
    Fabris C; Malesci A; Basso D; Bonato C; Del Favero G; Tacconi M; Meggiato T; Fogar P; Panozzo MP; Ferrara C
    Br J Cancer; 1991 Mar; 63(3):451-3. PubMed ID: 2003987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor markers carbohydrate antigens CA 19-9 and CA-50 and carcinoembryonic antigen in pancreatic cancer and benign diseases of the pancreatobiliary tract.
    Harmenberg U; Wahren B; Wiechel KL
    Cancer Res; 1988 Apr; 48(7):1985-8. PubMed ID: 3349472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and pancreatic juice carcinoembryonic antigen in pancreatic and biliary disease.
    Carr-Locke DL
    Gut; 1980 Aug; 21(8):656-61. PubMed ID: 7429329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour markers in pancreatic cancer.
    Haglund C; Roberts PJ; Kuusela P; Jalanko H
    Scand J Gastroenterol Suppl; 1986; 126():75-8. PubMed ID: 3470921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
    Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
    Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Carbohydrate antigen CA 19-9: value in pancreatic pathology].
    Venot J; Vincent D; Gainant A; Descottes B; Cessot F; Beck C
    Gastroenterol Clin Biol; 1986 Mar; 10(3):208-10. PubMed ID: 3460925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum levels of CA 19-9 and CA 50 in relation to Lewis blood cell status in patients with malignant and benign pancreatic disease.
    von Rosen A; Linder S; Harmenberg U; Pegert S
    Pancreas; 1993 Mar; 8(2):160-5. PubMed ID: 8460090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA 50 as a tumor marker in pancreatic cancer: a comparison with CA 19-9.
    Haglund C; Kuusela P; Jalanko H; Roberts PJ
    Int J Cancer; 1987 Apr; 39(4):477-81. PubMed ID: 3470260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttilä I; Alhava E
    Br J Cancer; 1992 May; 65(5):731-4. PubMed ID: 1316775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How does liver dysfunction influence serum CA 19-9 in pancreatic cancer?
    Basso D; Fabris C; Del Favero G; Piccoli A; Angonese C; Pasquali C; Castoro C; Plebani M; Leandro G; Burlina A
    Ital J Gastroenterol; 1990 Feb; 22(1):1-6. PubMed ID: 2131920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative studies of DU-PAN-2, carcinoembryonic antigen, and CA19-9 in the serum and bile of patients with pancreatic and biliary tract diseases: evaluation of the influence of obstructive jaundice.
    Ohshio G; Manabe T; Watanabe Y; Endo K; Kudo H; Suzuki T; Tobe T
    Am J Gastroenterol; 1990 Oct; 85(10):1370-6. PubMed ID: 2220731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of an oncofetal antigen (DU-PAN-2) in sera of patients with non-malignant hepatobiliary diseases and hepatomas.
    Haviland AE; Borowitz MJ; Killenberg PG; Lan MS; Metzgar RS
    Int J Cancer; 1988 Jun; 41(6):789-93. PubMed ID: 2836318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.